newsfilter
← Latest News
GlobeNewswire·

Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of Sep